You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 7,816,323

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,816,323

Title:	Methods of using corticotropin-releasing factor for the use of the treatment of cancer
Abstract:	Provided herein is a method for treating cancer in a human by administering a high dose of corticotropin-releasing factor (CRF).
Inventor(s):	Evans-Freke; Stephen (St. Thomas, VI)
Assignee:
Application Number:	12/758,621
Patent Claims:	1. A method for inhibiting tumor progression in a human patient with cancer, comprising administering human corticotropin-releasing factor (CRF) and bevacizumab to said patient; wherein said administering CRF comprises administering CRF to said patient subcutaneously at least once per day, wherein the cancer is breast cancer or colon cancer. 2. The method of claim 1, wherein the cancer is metastatic. 3. The method of claim 1, wherein the method further comprises monitoring tumor progression in the human. 4. The method of claim 1, wherein said administering CRF comprises administering CRF in a dose between 1 .mu.g/kg to 100 .mu.g/kg of body weight of the patient. 5. The method of claim 1, wherein said administering CRF comprises administering CRF in a dose of about 1 to about 4 mg. 6. The method of claim 1, wherein said administering CRF comprises administering CRF in a dose of about 1 mg. 7. The method of claim 1, wherein said administering CRF comprises administering CRF twice daily to said patient. 8. The method of claim 1, wherein said administering CRF comprises administering CRF to said patient at least once a day for a period of 2 weeks or more. 9. The method of claim 1, wherein said administering CRF comprises administering CRF to said patient at least once a day for a period of one month or more. 10. The method of claim 1, wherein said administering CRF comprises administering CRF to said patient at least once a day for a period of 3 months or more. 11. The method of claim 1, wherein bevacizumab is administered in a dose between 5 mg/kg and 15 mg/kg of body weight of the patient. 12. The method of claim 1, wherein bevacizumab is administered in a dose of 10 mg/kg of body weight of the patient. 13. The method of claim 1, wherein said administering bevacizumab is administered to the patient once a week, every two weeks or every three weeks. 14. The method of claim 1, wherein the cancer is breast cancer. 15. The method of claim 1, wherein the cancer is colon cancer.

Details for Patent 7,816,323

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2028-04-30
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.